Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings.

@article{CastroMalaspina2008TransplantationIR,
  title={Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings.},
  author={Hugo R Castro-Malaspina and Ann A Jabubowski and Esperanza B. Papadopoulos and Farid Boulad and James W Young and Nancy A Kernan and Miguel Angel Perales and Trudy N. Small and Katharine C Hsu and Michelle Chiu and Glenn Heller and Nancy H. Collins and Suresh C. Jhanwar and Marcel R M van den Brink and Stephen Nimer and Richard J O'reilly},
  journal={Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation},
  year={2008},
  volume={14 4},
  pages={458-68}
}
From 1985 to 2004, 49 patients with advanced myelodysplastic syndromes (MDS) (> or =5% blasts) or acute myeloid leukemia (AML) transformed from MDS underwent T cell depleted bone marrow or peripheral blood hematopoietic stem cell transplantation (HSCT) from HLA-identical siblings following conditioning with a myeloablative regimen that included total body irradiation (44 patients) or busulfan (5 patients). Thirty-six patients received chemotherapy (3 low dose and 33 induction doses) before… CONTINUE READING